BFM
MLYS icon

Boothbay Fund Management’s Mineralys Therapeutics MLYS Stock Holding History

Boothbay Fund Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,400
Closed -$165K – 1665
2025
Q1 		$165K Buy
+10,400
New +$120K ﹤0.01% 1193

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boothbay Fund Management's MLYS Position: Q2 2026 in Review

Boothbay Fund Management reduced its Mineralys Therapeutics (MLYS) stake by 85% in Q2 2026, selling an estimated $23.4M and leaving 147,402 shares worth $3.98M. The position accounts for 0.05% of the portfolio, ranked #424.

Boothbay Fund Management first reported a position in MLYS in Q2 2024 and has held it in 9 quarters since. The position peaked at $36M in Q4 2025. 226 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Boothbay Fund Management held 147,402 shares of Mineralys Therapeutics worth $3.98M as of Q2 2026.
  • Boothbay Fund Management sold 854,326 Mineralys Therapeutics shares in Q2 2026, an estimated $23.4M.
  • Mineralys Therapeutics made up 0.05% of Boothbay Fund Management's portfolio in Q2 2026, its #424 holding.
  • Boothbay Fund Management first reported a position in Mineralys Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • Boothbay Fund Management's Mineralys Therapeutics position peaked at $36M in Q4 2025.
  • 226 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.